| Literature DB >> 29368660 |
I Boldeanu1,2, J Perreault Bishop1, S Nepveu1, L-M Stevens2,3, G Soulez1,2, T M Kieser4, A Lamy5, N Noiseux2,3, C Chartrand-Lefebvre6,7.
Abstract
OBJECTIVE: To assess the prevalence and clinical significance of incidental findings identified during computed tomography imaging of coronary artery bypass grafts.Entities:
Keywords: Cardiac computed tomography; Coronary bypass graft; Emphysema; Incidental findings; Lung; Lung nodule
Mesh:
Year: 2018 PMID: 29368660 PMCID: PMC5784672 DOI: 10.1186/s13104-018-3168-1
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Patient characteristics and scan-related parameters
| Patient characteristics (n = 144 patients) | |
| Men/women | 122/22 |
| Age (years) [median (Q1–Q3)] | 69.0 (64.0–75.0) |
| Presence of IF (n, %) | 109 (75.7%) |
| BMI (kg/m2) [median (Q1–Q3)] | 27.40 (25.48–30.42) |
| Smokera (n, %) | 105 (72.9%) |
| Hypertension (n, %) | 126 (87.5%) |
| Diabetes (n, %) | 47 (32.6%) |
| Renal insufficiency (n, %) | 11 (7.6%) |
| CHF (n, %) | 5 (3.5%) |
| EuroScore | |
| 1 (n, %) | 17 (11.8%) |
| 2 (n, %) | 27 (18.8%) |
| 3 (n, %) | 45 (31.3%) |
| 4 (n, %) | 31 (21.5%) |
| 5 (n, %) | 19 (13.2%) |
| 6 (n, %) | 4 (2.8%) |
| 7 (n, %) | 0 (0.0%) |
| 8 (n, %) | 1 (0.7%) |
| Scan-related parameters | |
| Mean heart rate during scan (bpm) [median (Q1–Q3)] | 58.0 (53.0–64.0) |
| Prescan betablocker administration (n, %) | 65 (45.1%) |
| Prescan nitroglycerin administration (n, %) | 137 (95.1%) |
| Contrast agent (ml) [median (Q1–Q3)] | 102.0 (100.0–105.75) |
| Scan coverage (mm) [median (Q1–Q3)] | 250.0 (235.25–272.0) |
| DLP (mGy-cm) [median (Q1–Q3)] | 683.0 (469.0–897.0) |
| Effective doseb (mSv) [median (Q1–Q3)] | 9.6 (6.6–12.6) |
| ECG gating (prospective/retrospective) | 134/10 |
BMI Body mass index, bpm beats per minute, CHF congestive heart failure, EuroSCORE European System for Cardiac Operative Risk Evaluation, IF incidental findings, DLP dose-length product for CT angiography
aCurrent and former smokers were considered as smokers
bThe effective radiation dose was estimated by the product of the DLP and a conversion coefficient for the thorax (k = 0.014 mSv mGy−1 cm−1)
Prevalence of incidental cardiac and extracardiac findings
| Total IF | % of cardiac or extracardiac IF | % of all IF | Significant IF | |
|---|---|---|---|---|
| Incidental cardiac findings | ||||
| Left atrial dilatation | 34 | 47.9 | 16.1 | |
| Right atrial dilatation | 14 | 19.7 | 6.6 | |
| Aortic valve calcifications | 7 | 9.9 | 3.3 | |
| Lipomatous metaplasia (chronic myocardial infarction) | 3 | 4.2 | 1.4 | |
| Pericardial effusion | 3 | 4.2 | 1.4 | |
| Left ventricular hypertrophy | 2 | 2.3 | 1.0 | 1 |
| Atrial septal aneurysm | 1 | 1.4 | 0.5 | |
| Left atrial thrombus | 1 | 1.4 | 0.5 | |
| Other | 6 | 8.5 | 2.8 | |
| Total | 71 | 100.0 | 33.6 | 1 |
| Incidental extracardiac findings | ||||
| Pulmonary nodules | 54 | 38.6 | 25.6 | 23 |
| Emphysema | 21 | 15.0 | 10.0 | |
| Pleural effusion/thickening | 6 | 4.2 | 2.8 | |
| Thoracic aorta dilatation | 5 | 3.6 | 2.4 | |
| Enlarged mediastinal lymph nodes | 4 | 2.9 | 1.9 | 3 |
| Subclavian artery stenosis | 4 | 2,9 | 1.9 | |
| Main pulmonary artery dilatation | 2 | 1.4 | 1.0 | |
| Brachiocephalic artery stenosis | 1 | 0.7 | 0.5 | |
| Pulmonary infiltrates | 1 | 0.7 | 0.5 | 1 |
| Hiatal hernia | 17 | 12.1 | 8.1 | |
| Hepatic lesions | 10 | 7.1 | 4.7 | 6 |
| Abdominal aorta aneurysm | 1 | 0.7 | 0.5 | |
| Adrenal gland adenoma | 1 | 0.7 | 0.5 | |
| Thyroid nodules | 7 | 5.0 | 3.3 | 3 |
| Breast abnormalities | 2 | 1.4 | 1.0 | |
| Other | 4 | 2.9 | 1.9 | |
| Total | 140 | 100 | 66.4 | 36 |
Prevalence of incidental findings requiring action according to type of work-up and time period suggested for follow-up (n = 37 cases of IF)
| Type of IF (n, %) | |
| Pulmonary nodule | 23 (62.2) |
| Pulmonary infiltrate | 1 (2.7) |
| Enlarged mediastinal lymph nodes | 3 (8.1) |
| Left ventricular hypertrophy | 1 (2.7) |
| Thyroid nodule | 3 (8.1) |
| Hepatic lesion | 6 (16.2) |
| Type of recommended modality for follow-up (n, %) | |
| Computed tomography | 27 (73.0) |
| Ultrasonography | 10 (27.0) |
| Time frame of recommended follow-up (n, %), months | |
| 0–0.9 | 3 (8.1) |
| 0–2.9 | 11 (29.7) |
| 3–5.9 | 14 (37.8) |
| 6–8.9 | 3 (8.1) |
| 9–11.9 | 6 (16.2) |